Ronald Pepin Net Worth

Ronald Pepin biography

Dr. Ronald A. Pepin Ph.D. serves as Senior Vice President and Chief Business Officer of the Company. From June 2010 to April 2011, Dr. Pepin served as Vice President at Shire Pharmaceuticals. From August 2000 to December 2009, Dr. Pepin was Senior Vice President, Business Development at Medarex. Earlier in his career, Dr. Pepin was Executive Director of External Science and Technology at Bristol-Myers Squibb Company. Dr. Pepin received his B.A. from Tufts University and his Ph.D. in Genetics from Georgetown University.

What is the salary of Ronald Pepin?

As the Senior Vice President and Chief Business Officer of Celldex Therapeutics, the total compensation of Ronald Pepin at Celldex Therapeutics is $1,225,030. There are no executives at Celldex Therapeutics getting paid more.

How old is Ronald Pepin?

Ronald Pepin is 64, he's been the Senior Vice President and Chief Business Officer of Celldex Therapeutics since 2011. There are 7 older and 14 younger executives at Celldex Therapeutics. The oldest executive at Celldex Therapeutics Inc. is Herbert Conrad, 87, who is the Independent Director.

What's Ronald Pepin's mailing address?

Ronald's mailing address filed with the SEC is C/O CELLDEX THERAPEUTICS, INC., 53 FRONTAGE ROAD, SUITE 220, HAMPTON, NJ, 08827.

Insiders trading at Celldex Therapeutics

Over the last 16 years, insiders at Celldex Therapeutics have traded over $19,527,314 worth of Celldex Therapeutics stock and bought 273,450 units worth $1,157,166 . The most active insiders traders include Rajesh B Parekh, Garry Arthur Neil oraz Inc Medarex. On average, Celldex Therapeutics executives and independent directors trade stock every 69 days with the average trade being worth of $1,750,671. The most recent stock trade was executed by Samuel Bates Martin on 14 June 2024, trading 20,169 units of CLDX stock currently worth $204,917.

What does Celldex Therapeutics do?

celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response. celldex therapeutics (nasdaq: cldx) was founded based on a fundamental scientific belief that harnessing the power of the immune system would break significant barriers in drug development for a host of devastating diseases. the company's pipeline is comprised of therapeutic antibodies, antibody drug conjugates, immune system modulators and vaccines that we believe have a higher probability of success because they are targeted to specific patient populations with high unmet medical need whose diseases express specific markers, including many underserved or completely un-served orphan indications. this has created a leading pipeline in im

Celldex Therapeutics executives and stock owners

Celldex Therapeutics executives and other stock owners filed with the SEC include:

• Ronald Pepin,
  Senior Vice President and Chief Business Officer
• Anthony Marucci,
  President, Chief Executive Officer, Director
• Anthony S. Marucci M.B.A.,
  Founder, Pres, CEO & Director
• Tibor Keler,
  Executive Vice President and Chief Scientific Officer
• Dr. Tibor Keler,
  Founder, Chief Scientific Officer & Exec. VP
• Dr. Diane C. Young M.D.,
  Sr. VP & Chief Medical Officer
• Margo Heath-Chiozzi,
  Senior Vice President - Regulatory Affairs
• Sam Martin,
  Chief Financial Officer, Senior Vice President, Secretary
• Richard Wright,
  Senior Vice President, Chief Commercial Officer
• Dr. Margo Heath-Chiozzi M.D.,
  Sr. VP of Regulatory Affairs
• Elizabeth Crowley,
  Senior Vice President, Chief Product Development Officer
• Sam Martin,
  Sr. VP, CFO, Sec. & Treasurer
• Elizabeth Crowley,
  Chief Product Devel. Officer & Sr. VP
• Karen Shoos,
  Independent Chairman of the Board
• Keith Brownlie,
  Independent Director
• James Marino,
  Independent Director
• Harry Penner,
  Independent Director
• Herbert Conrad,
  Independent Director
• Diane Young,
  Senior Vice President, Chief Medical Officer
• Sarah Cavanaugh,
  Senior Vice President - Corporate Affairs and Administration
• Prof. Joseph P. Schlessinger Ph.D.,
  Co-Founder & Member of Scientific Advisory Board
• Dr. Richard M. Wright Ph.D.,
  Chief Commercial Officer & Sr. VP
• Dr. Ronald A. Pepin,
  Chief Bus. Officer & Sr. VP
• Freddy A. Jimenez Esq.,
  Sr. VP & Gen. Counsel
• Patrick Till,
  Sr. Director of Investor Relations & Corp. Communications
• Sarah Cavanaugh,
  Sr. VP of Corp. Affairs & Admin.
• Theresa La Vallee,
  SVP, Reg.& Precision Medicine
• Larry Ellberger,
  Director
• George Elston,
  Director
• Gerald Ph D Mc Mahon,
  Director
• Avery W Catlin,
  Sr. VP & CFO
• Den Broek Richard Van,
  Director
• Rita Jain,
  
• Timothy M Shannon,
  Director
• Rajesh B Parekh,
  Director
• Charles R Schaller,
  Director
• Inc Medarex,
  10% owner
• Ronald C Newbold,
  Sr. VP, Business Dev.
• Cheryl Cohen,
  
• Freddy A. Jimenez,
  SVP & GENERAL COUNSEL
• Garry Arthur Neil,